With a deal worth up to $1.3 billion, Takeda could get its hands on a “potentially best-in-class” third-generation BCR-ABL ...

Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), ...

A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations ...

Despite some contract manufacturing growing pains in the post-COVID era, MilliporeSigma, the U.S. | MilliporeSigma is ...

In the wake of the Supreme Court’s decision to preserve mail-order access to the abortion pill mifepristone, leaders from ...

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the ...

A maker of health education podcasts—including installments sponsored by major biopharma and medtech players—is adding a ...

During a recent investor event dedicated to the newly expanded oncology business, Pfizer unveiled a goal to have ...

Through a licensing deal with a Chinese biotech, AbbVie is the latest Big Pharma to bet on TL1A in immunology. | Through a ...

With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in ...

As Johnson & Johnson has tried to resolve talcum powder lawsuits that have been consolidated in a multidistrict litigation in ...

After months of sharp share-price declines, WuXi AppTec and WuXi Biologics enjoyed a brief respite Wednesday amid new ...